Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Among authors: oriol a. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J. Rosiñol L, et al. Among authors: oriol a. J Clin Oncol. 2007 Oct 1;25(28):4452-8. doi: 10.1200/JCO.2007.12.3323. Epub 2007 Sep 4. J Clin Oncol. 2007. PMID: 17785704 Clinical Trial.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Among authors: oriol a. Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5. Haematologica. 2008. PMID: 18322252 Free article. Clinical Trial.
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group. Oriol A, et al. Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145276 Free PMC article.
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J. Mateos MV, et al. Among authors: oriol a. Clin Cancer Res. 2010 Jun 15;16(12):3260-9. doi: 10.1158/1078-0432.CCR-10-0469. Epub 2010 Jun 8. Clin Cancer Res. 2010. PMID: 20530693 Clinical Trial.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF. Mateos MV, et al. Among authors: oriol a. Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23. Lancet Oncol. 2010. PMID: 20739218 Clinical Trial.
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Alegre A, Aguado B, Giraldo P, Ríos E, Cánovas A, Ibáñez Á, Castillo I, Hernández MT, Oriol A, Palomera L, Rodríguez JN, García FL, Calvo JM, Martínez-Chamorro C, de la Serna J, Lahuerta JJ. Alegre A, et al. Among authors: oriol a. Int J Hematol. 2011 Mar;93(3):351-360. doi: 10.1007/s12185-011-0785-z. Epub 2011 Mar 1. Int J Hematol. 2011. PMID: 21360065 Clinical Trial.
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AI, de Paz R, Laraña JG, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F, Bladé J, Orfao A, Lahuerta JJ, San Miguel JF. Paiva B, et al. Among authors: oriol a. J Clin Oncol. 2011 Apr 20;29(12):1627-33. doi: 10.1200/JCO.2010.33.1967. Epub 2011 Mar 14. J Clin Oncol. 2011. PMID: 21402611 Clinical Trial.
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Martín A, Díaz-Mediavilla J, de Arriba F, Palomera L, Hernández JM, Sureda A, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, Fernández M, García-Sanz R, Vidriales MB, Bladé J, Lahuerta JJ, San Miguel JF. Mateos MV, et al. Among authors: oriol a. Blood. 2011 Oct 27;118(17):4547-53. doi: 10.1182/blood-2011-04-345801. Epub 2011 Sep 6. Blood. 2011. PMID: 21900193 Free article. Clinical Trial.
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.
Rosiñol L, García-Sanz R, Lahuerta JJ, Hernández-García M, Granell M, de la Rubia J, Oriol A, Hernández-Ruiz B, Rayón C, Navarro I, García-Ruiz JC, Besalduch J, Gardella S, López Jiménez J, Díaz-Mediavilla J, Alegre A, San Miguel J, Bladé J; PETHEMA/Spanish Myeloma Group. Rosiñol L, et al. Among authors: oriol a. Haematologica. 2012 Apr;97(4):616-21. doi: 10.3324/haematol.2011.051441. Epub 2011 Nov 4. Haematologica. 2012. PMID: 22058223 Free PMC article. Clinical Trial.
383 results